3-Month, Single Site or Multi-Site, Double Blind, Randomized, Placebo-Controlled, Parallel-Group Trial to Evaluate the Safety Tolerability and Potential Effects of the Dietary Supplement Anatabloc(R) in Subjects With Alzheimer's Disease
Phase of Trial: Phase II
Latest Information Update: 05 May 2015
At a glance
- Drugs Anatabine (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Acronyms ASAP
- Sponsors Rock Creek Pharmaceuticals
- 10 Jun 2017 Biomarkers information updated
- 29 Apr 2015 Status changed from suspended to discontinued as reported by ClinicalTrials.gov record.
- 05 Mar 2014 Status has changed from recruiting to suspended as reported by ClinicalTrials.gov record.